Short Interest in Daré Bioscience, Inc. (NASDAQ:DARE) Grows By 118.8%

Daré Bioscience, Inc. (NASDAQ:DARE) was the recipient of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 55,800 shares, an increase of 118.8% from the November 15th total of 25,500 shares. Based on an average trading volume of 40,500 shares, the short-interest ratio is presently 1.4 days. Approximately 0.7% of the shares of the company are sold short.

Institutional Trading of Daré Bioscience

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC raised its position in Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the SEC. 6.70% of the stock is owned by institutional investors.

Daré Bioscience Trading Down 0.3 %

DARE stock opened at $3.18 on Friday. The business has a 50 day simple moving average of $3.56 and a 200-day simple moving average of $3.77. The company has a market capitalization of $27.67 million, a P/E ratio of -5.38 and a beta of 1.27. Daré Bioscience has a twelve month low of $3.05 and a twelve month high of $7.56.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a report on Friday, November 15th.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.